Nantkwest (NASDAQ:NK) Upgraded at ValuEngine

Nantkwest (NASDAQ:NK) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, ValuEngine reports.

Other equities analysts have also issued research reports about the company. Citigroup lowered Nantkwest from a “neutral” rating to a “sell” rating and lowered their price objective for the stock from $1.25 to $1.00 in a research note on Thursday, May 30th. Zacks Investment Research lowered Nantkwest from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $2.00.

Nantkwest stock traded up $0.01 during mid-day trading on Thursday, reaching $1.27. 168,685 shares of the company were exchanged, compared to its average volume of 241,387. The firm’s fifty day simple moving average is $1.15. Nantkwest has a 12 month low of $0.93 and a 12 month high of $4.23. The company has a current ratio of 4.09, a quick ratio of 4.09 and a debt-to-equity ratio of 0.08. The company has a market cap of $125.31 million, a price-to-earnings ratio of -1.04 and a beta of 2.33.

Nantkwest (NASDAQ:NK) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.22) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.01. Nantkwest had a negative return on equity of 52.68% and a negative net margin of 184,234.05%. The firm had revenue of $0.01 million for the quarter. As a group, research analysts expect that Nantkwest will post -0.82 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning bought a new position in shares of Nantkwest in the 1st quarter valued at $28,000. Edge Wealth Management LLC increased its stake in shares of Nantkwest by 100.0% in the 1st quarter. Edge Wealth Management LLC now owns 20,000 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 10,000 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Nantkwest in the 4th quarter valued at $84,000. Deutsche Bank AG increased its stake in shares of Nantkwest by 165.9% in the 4th quarter. Deutsche Bank AG now owns 149,330 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 93,170 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Nantkwest by 338.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 180,595 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 139,431 shares during the last quarter. Institutional investors own 8.10% of the company’s stock.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Recommended Story: What is a Roth IRA?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.